Last reviewed · How we verify

Anhui Shi, MD — Portfolio Competitive Intelligence Brief

Anhui Shi, MD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
atezolizumab or durvalumab atezolizumab or durvalumab phase 3 PD-1/PD-L1 inhibitor PD-L1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
  2. Cellvax Therapeutics Inc · 1 shared drug class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  4. EMD Serono · 1 shared drug class
  5. EMS · 1 shared drug class
  6. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 shared drug class
  7. Fujian Cancer Hospital · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Anhui Shi, MD:

Cite this brief

Drug Landscape (2026). Anhui Shi, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anhui-shi-md. Accessed 2026-05-16.

Related